These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 11569533)

  • 1. Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidase.
    Austin NE; Baldwin SJ; Cutler L; Deeks N; Kelly PJ; Nash M; Shardlow CE; Stemp G; Thewlis K; Ayrton A; Jeffrey P
    Xenobiotica; 2001; 31(8-9):677-86. PubMed ID: 11569533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
    Kamath AV; Wang J; Lee FY; Marathe PH
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cynomolgus monkey as a surrogate for human aldehyde oxidase metabolism of the EGFR inhibitor BIBX1382.
    Hutzler JM; Cerny MA; Yang YS; Asher C; Wong D; Frederick K; Gilpin K
    Drug Metab Dispos; 2014 Oct; 42(10):1751-60. PubMed ID: 25035284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): A potent and selective dopamine D(3) receptor antagonist with high oral bioavailability and CNS penetration in the rat.
    Stemp G; Ashmeade T; Branch CL; Hadley MS; Hunter AJ; Johnson CN; Nash DJ; Thewlis KM; Vong AK; Austin NE; Jeffrey P; Avenell KY; Boyfield I; Hagan JJ; Middlemiss DN; Reavill C; Riley GJ; Routledge C; Wood M
    J Med Chem; 2000 May; 43(9):1878-85. PubMed ID: 10794704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A.
    Reavill C; Taylor SG; Wood MD; Ashmeade T; Austin NE; Avenell KY; Boyfield I; Branch CL; Cilia J; Coldwell MC; Hadley MS; Hunter AJ; Jeffrey P; Jewitt F; Johnson CN; Jones DN; Medhurst AD; Middlemiss DN; Nash DJ; Riley GJ; Routledge C; Stemp G; Thewlis KM; Trail B; Vong AK; Hagan JJ
    J Pharmacol Exp Ther; 2000 Sep; 294(3):1154-65. PubMed ID: 10945872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro hepatic metabolism of ABT-418 in chimpanzee (Pan troglodytes). A unique pattern of microsomal flavin-containing monooxygenase-dependent stereoselective N'-oxidation.
    Rodrigues AD; Kukulka MJ; Ferrero JL; Cashman JR
    Drug Metab Dispos; 1995 Oct; 23(10):1143-52. PubMed ID: 8654204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SB-277011 GlaxoSmithKline.
    Remington G; Kapur S
    Curr Opin Investig Drugs; 2001 Jul; 2(7):946-9. PubMed ID: 11757796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.
    Lin JH; Chiba M; Balani SK; Chen IW; Kwei GY; Vastag KJ; Nishime JA
    Drug Metab Dispos; 1996 Oct; 24(10):1111-20. PubMed ID: 8894513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SB-239063, a potent and selective inhibitor of p38 map kinase: preclinical pharmacokinetics and species-specific reversible isomerization.
    Ward KW; Proksch JW; Azzarano LM; Salyers KL; McSurdy-Freed JE; Molnar TM; Levy MA; Smith BR
    Pharm Res; 2001 Sep; 18(9):1336-44. PubMed ID: 11683250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of brimonidine metabolism with rat, rabbit, dog, monkey and human liver fractions and rabbit liver aldehyde oxidase.
    Acheampong AA; Chien DS; Lam S; Vekich S; Breau A; Usansky J; Harcourt D; Munk SA; Nguyen H; Garst M; Tang-Liu D
    Xenobiotica; 1996 Oct; 26(10):1035-55. PubMed ID: 8905918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The in vitro hepatic metabolism of ABT-418, a cholinergic channel activator, in rats, dogs, cynomolgus monkeys, and humans.
    Rodrigues AD; Ferrero JL; Amann MT; Rotert GA; Cepa SP; Surber BW; Machinist JM; Tich NR; Sullivan JP; Garvey DS
    Drug Metab Dispos; 1994; 22(5):788-98. PubMed ID: 7530622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disposition of CP-671, 305, a selective phosphodiesterase 4 inhibitor in preclinical species.
    Kalgutkar AS; Choo E; Taylor TJ; Marfat A
    Xenobiotica; 2004 Aug; 34(8):755-70. PubMed ID: 15690763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [In vitro metabolism of anti-tumor compound E7 in different species of liver microsomes].
    Tang MH; Wang HR; Wang CY; Ye HY
    Zhongguo Zhong Yao Za Zhi; 2016 May; 41(9):1739-1743. PubMed ID: 28891627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytochromes P450 in cynomolgus monkeys mutagenically activate 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) but not 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx).
    Sadrieh N; Snyderwine EG
    Carcinogenesis; 1995 Jul; 16(7):1549-55. PubMed ID: 7614688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldehyde oxidase-dependent marked species difference in hepatic metabolism of the sedative-hypnotic, zaleplon, between monkeys and rats.
    Kawashima K; Hosoi K; Naruke T; Shiba T; Kitamura M; Watabe T
    Drug Metab Dispos; 1999 Mar; 27(3):422-8. PubMed ID: 10064576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA).
    Rioux N; Smith S; Korpal M; O'Shea M; Prajapati S; Zheng GZ; Warmuth M; Smith PG
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):151-160. PubMed ID: 30386887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and elucidation of the rates and routes of N-glucuronidation of PF-592379, an oral dopamine 3 agonist in rat, dog, and human.
    Attkins N; Betts A; Hepworth D; Heatherington AC
    Xenobiotica; 2010 Nov; 40(11):730-42. PubMed ID: 20836725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic, intestinal, renal, and plasma hydrolysis of prodrugs in human, cynomolgus monkey, dog, and rat: implications for in vitro-in vivo extrapolation of clearance of prodrugs.
    Nishimuta H; Houston JB; Galetin A
    Drug Metab Dispos; 2014 Sep; 42(9):1522-31. PubMed ID: 24994071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cynomolgus monkey liver aldehyde oxidase: extremely high oxidase activity and an attempt at purification.
    Sugihara K; Katsuma Y; Kitamura S; Ohta S; Fujitani M; Shintani H
    Comp Biochem Physiol C Toxicol Pharmacol; 2000 May; 126(1):53-60. PubMed ID: 11048665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.